Download PDF
Hamostaseologie 1987; 07(05): 120-127
DOI: 10.1055/s-0038-1660541
Originalarbeit
Schattauer GmbH

Prostaglandintherapie bei arteriellen Durchblutungsstörungen

H. Sinzinger
1   Atheroskleroseforschungsgruppe (ASF) Wien, 2. Medizinische Abteilung, Allgemeine Poliklinik, Wien
,
P. Fitscha
1   Atheroskleroseforschungsgruppe (ASF) Wien, 2. Medizinische Abteilung, Allgemeine Poliklinik, Wien
› Author Affiliations
Further Information

Publication History

Publication Date:
25 June 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • LITERATUR

  • 1 Ambrus JL, Taheri P, Killion D, Donaldson G. Clinical experience with prostaglandin El in the treatment of arteriosclerosis obliterans. J Med 1983; 14: 1.
    PubMedGoogle Scholar
  • 2 Belch JJF, McKay A, McArdle B, Leiber-man P, Pollock JG, Lowe GDO, Forbes CD, Prentice CRM. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial. Lancet 1983; I: 315.
    PubMedGoogle Scholar
  • 3 Biedermann H. Unsere ersten Erfahrungen bei der Behandlung inoperabler Ischämie-und Gangränbeine mit Prostaglandin Ej (PGEj). Angio Archiv 1982; 03: 98.
    PubMedGoogle Scholar
  • 4 Biedermann H. Results of intra-arterial long-term infusion therapy with prostaglandin Ej (PGE) for arterial circulatory disturbances in the extremities in stages III and/or IV. Inter Angio 1984; 03: 59.
    PubMedGoogle Scholar
  • 5 Cannon AM, Jamieson CW, Savage GF. Initial experiences in the use of a prostacyclin analogue, iloprost, in critical ischaemia of the lower limb. In Platelets, Prostaglandins and Cardiovascular System. Florence; C127 1984
    Google Scholar
  • 6 Carlson LA, Eriksson I. Femoral-artery infusion of prostaglandin E! in severe peripheral vascular disease. Lancet 1973; I: 155.
    PubMedGoogle Scholar
  • 7 Carlson LA, Olsson AG. Intravenous prostaglandin E1 in severe peripheral vascular disease. Lancet 1976; II: 810.
    PubMedGoogle Scholar
  • 8 Chiesa R, Vicari A, Mari G, Galimberti M, DiCarlo V, Pozza G. Use of stable prostacyclin analogue ZK 36374 to treat lower limb ischaemia. Lancet 1985; II: 95.
    PubMedGoogle Scholar
  • 9 Creutzig A, Lux M, Dau D, Alexander K. Intermittent intraarterial short-time infusion of prostaglandin Ej for treatment of arterial occlusive disease. In: Prostaglandins and Other Eicosanoids in the Cardiovascular System. Schrör K. (ed) Basel: Karger; 1985: 341.
    Google Scholar
  • 10 Diehm C. Plazebo-kontrollierte doppelblinde 13-Center-Studie zum Nachweis der therapeutischen Wirksamkeit von Iloprost bei Patienten mit arterieller Verschlußkrankheit (Stadium IV). In: 93. Tag. Verh Dtsch Ges Inn Med München. Bergmann: 1987. (im Druck)
    Google Scholar
  • 11 Eklund AE, Eriksson G, Olsson AG. A controlled study showing significant short term effects of prostaglandin E! in healing of ischaemic ulcers of the lower limb in man. Prostaglandins Leukotrienes Med 1982; 08: 265.
    CrossrefPubMedGoogle Scholar
  • 12 Feldman SM, Alpert J, Dick LS, Brief DK, Goldkranz R, Brener BJ, Parsonnet V. Clinical observations with intravenous prostaglandin Et in peripheral vascular disease. J Med Soc N J 1982; 79: 985.
    PubMedGoogle Scholar
  • 13 Fitscha P, Sinzinger H, Greenberg H, Jennifer H, Linet O. Prostacyclin in peripheral vascular disease -a double-blind trial in 108 patients. Thromb Haemost 1985; 54: 296.
    PubMedGoogle Scholar
  • 14 Fitscha P, Sinzinger H, Tiso B. Prostaglandin Ej bei peripherer Verschlußkrankheit. Z Kardiol 1985; 74: 105.
    PubMedGoogle Scholar
  • 15 Golub M, Zia P, Matsuno M, Horton R. Metabolism of prostaglandin A! and Et in man. J Clin Invest 1975; 56: 1404.
    CrossrefPubMedGoogle Scholar
  • 16 Gruss JD, Bartels D, Ohta T, Machado JL, Schlechtweg B. Conservative treatment of inoperable arterial occlusions of the lower extremities with intraarterial prostaglandin Ej. Br J Surg 1982; 69: 511.
    PubMedGoogle Scholar
  • 17 Hach W, Özen J, Schirmers U. Intermittent intraarterial infusion of PGErα-CG in patients with peripheral arterial disease in stage lib. In: Prostaglandins and Other Eicosanoids in the Cardiovascular System. Schrör K. (ed) Basel: Karger; 1985: 365.
    Google Scholar
  • 18 Hossmann V, Heinen A, Auel H, Fitzgerald GA. A randomized placebo controlled trial of prostacyclin (PGI2) in peripheral arterial disease. Thromb Res 1981; 22: 481.
    CrossrefPubMedGoogle Scholar
  • 19 Hossmann V. Effects of iloprost in patients with peripheral arterial occlusive disease. In: Iloprost (ZK 36374), a Novel Prostacyclin Analogue in Cardiovascular Disease. Scientific Symposium, Düsseldorf: Schering AG; 1984: 57.
    Google Scholar
  • 20 Hossmann V, Auel H, Rücker W, Schrör K. Prolonged infusion of prostacyclin in patients with advanced stages of peripheral vascular disease: a placebo-controlled crossover study. Klin Wochenschr 1984; 62: 1108.
    CrossrefPubMedGoogle Scholar
  • 21 Hossmann V, Auel H, Schrör K. ZK 36374, a stable prostacyclin analogue, for the treatment of advanced stages of obliterative arterial disease. Int. Symp. on Conversative Therapy of Arterial Occlusion Disease. Bonn; A28 1984
    Google Scholar
  • 22 Kaliman J, Fitscha P, Barth H, Sinzinger H. Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue. In: Prostaglandins in Clinical Research. Sinzinger H, Schrör K. (eds) Philadelphia: Alan R. Liss; 1987 (im Druck)
    Google Scholar
  • 23 Kaukinen S, Pessi T, Ylitalo P, Krais T, Vapaatalo H. Clinical study of ZK 36374: a new stable prostacyclin analog for treatment of peripheral vascular disease. In: Prostacyclin. Clinical Trials. Gryglewski RJ, Szcze-klik A, McGif JC. (eds) New York: Raven Press; 1985: 23.
    Google Scholar
  • 24 Negus D, Irving JD, Friedgood A. Intra-arterial prostacyclin compared to praxilene in the management of advanced atherosclerotic lower limb ischemia. In: Prostacyclin. Clinical Trials. Gryglewski RJ, Szczeklik A, McGiff JC. (eds) New York: Raven Press; 1985: 107.
    Google Scholar
  • 25 Nizankowski R, Krolikowski W, Bielato-wicz J, Schaller J, Szczeklik A. Prostacyclin for ischemic ulcers in peripheral arterial disease: a random assignement, placebocontrolled study. In: Prostacyclin. Clinical Trials. Gryglewski RJ, Szczeklik A, McGiff JC. (eds) New York: Raven Press; 1985: 15.
    Google Scholar
  • 26 Olsson AG, Jogestrand T. Effects of prostaglandin E in peripheral artery disease. In: International Conference on Atherosclerosis. Carlson LA. (ed) New York: Raven Press; 1978: 403.
    Google Scholar
  • 27 Olsson AG. Intravenous prostacyclin for ischaemic ulcers in peripheral artery disease. Lancet 1980; II: 1076.
    PubMedGoogle Scholar
  • 28 Olsson AG, Eriksson G, Eklund AE. Double-blind controlled study of the effect of prostaglandin E1 on healing of ischemic ulcers of the lower limb. In: Prostaglandins in Clinical Medicine. Cardiovascular and Thrombotic Disorders. Wu KK, Rossi EC. (eds) Chicago -London: Year Book Medical; 1981: 225.
    Google Scholar
  • 29 Olsson AG, Nilsson E. The effect of intravenous prostacyclin on resting pain and healing of ischaemic ulcers in peripheral artery disease. Prostagl Med 1981; 06: 329.
    CrossrefPubMedGoogle Scholar
  • 30 Pardy BC, Lewis JD, Eastcott HHG. Preliminary experience with prostaglandins Ej and I2 in peripheral vascular disease. Surgery 1980; 88: 826.
    PubMedGoogle Scholar
  • 31 Pilger E, Juan H. Vorläufige Ergebnisse einer Prostaglandin-ErTherapie bei peripherer obliterierender Arteriopathie. Wien Klin Wochenschr 1983; 95: 263.
    PubMedGoogle Scholar
  • 32 Rhodes RS, Heard SE. Detrimental effect of high-dose prostaglandin Ei in the treatment of ischemic ulcers. Surgery 1983; 93: 839.
    PubMedGoogle Scholar
  • 33 Sakaguchi S, Kusaba A, Mishima Y, Ka-miya K, Nishimura A, Furukawa K, Shio-noya S, Kawashima M, Katsumura K, Nishimura A. A multiclinical double-blind study with PGEi (a-cyclodextrin clathrate) in patients with ischemic ulcer of the extremities. VASA 1978; 07: 263.
    PubMedGoogle Scholar
  • 34 Schuler JJ, Flanigan DP, Holcroft JW, Ursprung JJ, Mohrland JS, Pyke E. The efficacy of prostaglandin Ej in the treatment of lower ischemia ulcers secondary to peripheral vascular occlusive disease: results of a prospective, randomized, double-blind, multicenter trial. Vase Surg 1984; 01: 160.
    PubMedGoogle Scholar
  • 35 Seino Y, Rose HB, Kanazawa M, Vyden JK, Wall FJ. Double-blind study of papaverine hydrochloride on the efficacy in the treatment of intermittent claudication. An-giology 1983; 34: 257.
    CrossrefPubMedGoogle Scholar
  • 36 Sethi GK, Scott SM, Takaro T. Effect of intra-arterial infusion of PGEj in patients with severe ischemia of lower extremity. J Cardiovasc Surg 1980; 21: 185.
    PubMedGoogle Scholar
  • 37 Sinzinger H, Fitscha P, Popovic R, Krais T. Clinical and platelet effects of ZK 36374 (Iloprost) -a stable prostacyclin analogue -in peripheral vascular disease. Thromb Haemost 1985; 54: 294.
    PubMedGoogle Scholar
  • 38 Szczeklik A, Nizankowski R, Skawinski S, Szczeklik J, Gluszko P, Gryglewski RJ. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet 1979; I: 1111.
    PubMedGoogle Scholar
  • 39 Szczeklik A, Gryglewski RJ, Nizankowski R, Skawinski S, Gluszko P, Korbut R. Prostacyclin therapy in peripheral arterial disease. Thromb Res 1980; 19: 191.
    CrossrefPubMedGoogle Scholar